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Background: Murine gammaherpesvirus 68 (MHV-68) is used as a model to study the function of
gammaherpesvirus glycoproteins. gp150 of MHV-68, encoded by open reading frame M7, is a positional homolog
of gp350/220 of EBV and of gp35/37 of KSHV. Since it had been proposed that gp350/220 of EBV might be a
suitable vaccine antigen to protect from EBV-associated diseases, gp150 has been applied as a model vaccine in
the MHV-68 system. When analyzing the function of gp150, previous studies yielded conflicting results on the role
of gp150 in latency amplification, and disparities between the mutant viruses which had been analyzed were
blamed for the observed differences.
Results: To further develop MHV-68 as model to study the function of gammaherpesvirus glycoproteins in vivo, it
is important to know whether gp150 contributes to latency amplification or not. Thus, we re-evaluated this
question by testing a number of gp150 mutants side by side. Our results suggest that gp150 is dispensable for
latency amplification. Furthermore, we investigated the effect of vaccination with gp150 using gp150-containing
exosomes. Vaccination with gp150 induced a strong humoral and cellular immune response, yet it did not affect a
subsequent MHV-68 challenge infection.
Conclusions: In this study, we found no evidence for a role of gp150 in latency amplification. The previously
observed contradictory results on the role of gp150 in latency amplification were not related to differences
between the mutant viruses which had been used.
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Infection of cells by herpesviruses is orchestrated by sev-
eral viral glycoproteins which function either separately or
within multiprotein-complexes to mediate virus entry [1].
Murine gammaherpesvirus 68 (MHV-68) has been exten-
sively used as a model to study the function of gammaher-
pesvirus glycoproteins [2-5]. Glycoprotein 150 (gp150) of
MHV-68 is encoded by open reading frame M7 [6] and
has been shown to be virion-associated [7]. It is a pos-
itional homolog of gp350/220 of EBV and of gp35/37 of
KSHV [6], and it has been shown to be important for vir-
ion release [8,9] and antibody evasion [10]. When studying* Correspondence: h.adler@helmholtz-muenchen.de
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reproduction in any medium, provided the orthe function of gp150, both de Lima et al. [9] and Stewart
et al. [8] found that mutation of gp150 did not consider-
ably affect lytic replication in vivo and in vitro, except
from a moderate deficit in release of extracellular virus.
However, Stewart et al. observed a reduction in spleno-
megaly and in the number of latently infected cells during
latency amplification. In contrast, de Lima et al. reported
normal latency amplification by gp150-deficient MHV-68.
Clearly, to further develop MHV-68 as model for studying
the function of gammaherpesvirus glycoproteins in vivo, it
is important to know whether gp150 reliably contributes
to latency amplification. Here, we present data supporting
that gp150 is dispensable for latency amplification but it
remains possible that it might play a role under different,
so far ill-defined circumstances.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Previously, conflicting results have been published on
the role of gp150 in latency amplification [8,9], and sev-
eral hypotheses were raised to explain these discrepan-
cies: i) Stewart et al. introduced a large deletion in the
MHV-68 genome to disrupt gp150 which might have in-
advertently disrupted additional viral functions, e.g. un-
known latency transcripts [2]. On the other hand, the
mutations made by de Lima et al. might allow the ex-
pression of a truncated but still functional gp150 protein
[8]. ii) Stewart et al. investigated only a single mutant
while de Lima et al. constructed two independent
mutants. The latter can be considered to be a superior
strategy to study a gene function [2]. Although Stewart
et al. carefully analyzed their mutant by various standard
procedures, and even analyzed the viral transcriptome
by DNA oligonucleotide microarray, it is formally pos-
sible that subtle defects escaped their analysis. iii) Stew-
art et al. also constructed a BAC-based revertant but
BAC-based revertants do not control for problems after
virus reconstitution [2].
gp150 and latency amplification
To address the above mentioned points, we re-evaluated
whether gp150 plays a role during latency amplification.
For this purpose, we analyzed the following viruses: i)
the original mutant (vgp150Δ) which was constructed in
our own laboratory and which has been described in
Stewart et al. [8]; ii) a second gp150 mutant (vgp150Δ_2)
which we independently reconstituted from the same
BAC clone from which the original mutant vgp150Δ had
been derived - to test for aberrations which might have
occurred during reconstitution; iii) a M7-FRT mutant
constructed exactly as described by de Lima et al. [9], to
test whether the different size and position of the dele-
tion affect the phenotype. All mutant viruses were com-
pared to the revertant virus vgp150R, which had been
constructed in our own laboratory and shown to behave
exactly like parental (wild-type) virus [8].
To analyze the role of gp150 on latency amplification,
we infected C57BL/6 mice intranasally (i.n.) with 5 × 104
PFU. At day 17 after infection, a time point when la-
tency amplification is going on, spleens were harvested
and the spleen weights (as a measure of splenomegaly)
were determined. Furthermore, the numbers of latently
infected cells were determined by a limiting dilution re-
activation assay and the latent viral load was measured
by quantitative real time PCR. As shown in Figure 1A-C,
we did not observe significant differences in any of
these parameters (two-tailed Student’s t-test). To rule
out that this finding was specific for C57BL/6 mice, we
additionally performed an experiment in BALB/c mice,
comparing mutant virus vgp150Δ with its revertant
(Figure 1D-F). Again, no significant differences wereobserved (two-tailed Student’s t-test). Thus, our data sug-
gest that gp150 is not important for latency amplification
and clearly show that the different results obtained in the
previous studies by Stewart et al. [8] and de Lima et al.
[9] are not caused by differences between the mutant
viruses which had been used. This finding clearly differs
from studies analyzing the role of the MHV-68 open
reading frame M3. M3 is a broad-spectrum chemokine
binding protein which inhibits chemokine action [11,12].
Disruption of M3 by insertion of a β-galactosidase ex-
pression cassette significantly compromised latency es-
tablishment [13], while a M3 mutant generated by
insertion of a translational stop codon followed by a
frame shift showed normal latency establishment [14]. In
this case, the different observations have been attributed
to the insertion of the β-galactosidase expression cassette
which may have caused additional adverse effects not
related to mutation of M3 [15]. Since the diverse results
obtained for gp150 deletions are obviously not related to
differences between the mutant viruses which had been
used, we speculate that they might be due to differences
of the host, the host environment or to subtle differences
in the methods applied and time points analyzed. For ex-
ample, we infected mice at 6 to 8 weeks of age with
5 × 104 PFU, whereas Stewart et al. infected mice at 4 to
6 weeks of age with 4 × 105 PFU [8]. While we analyzed
splenomegaly by measuring the spleen weight and the
number of ex vivo reactivating cells by ex vivo limiting
dilution reactivation assay at day 17 after infection, Stew-
art et al. used the spleen cell number as a measure of
splenomegaly and infectious center assays to determine
the number of ex vivo reactivating cells at days 10, 14
and 21 after infection [8]. In addition, different experi-
mental outcomes may correlate with specific properties
of the respective mouse facilities. For example, moving
Atg16L1-deficient mice from conventional barrier living
conditions to an enhanced barrier facility has recently
been shown to dramatically change their phenotype [16].
It was shown that this was due to the presence of a par-
ticular strain of norovirus in one of the facilities.
gp150 and vaccination
The MHV-68 model might be very useful to define effect-
ive strategies for gammaherpesvirus vaccination [17].
Since it had been proposed that gp350/220 might be a
suitable vaccine antigen to protect from EBV-associated
diseases [18], the positional homolog of MHV-68, gp150,
has been used as a model vaccine in the MHV-68 system.
If gp150 contributes to the extent of splenomegaly and to
the frequency of latently infected cells during latency amp-
lification in the spleen, as proposed by Stewart et al. [8], it
would be reasonable to expect a reduction of both para-
meters after vaccination with gp150. Indeed, vaccination

































































































































Figure 1 gp150 does not contribute to latency amplification. A) and D) Spleen weights, B) and E) Ex vivo reactivation of splenocytes and C)
and F) Viral genomic load in the spleen. C57BL/6 mice (A-C) or Balb/c mice (D-F) were infected i.n. with 5×104 PFU. At day 17 after infection,
spleens were harvested and the spleen weights were taken (the spleen weight of uninfected mice of the same age was in the range of 80 to
120 mg; data not shown). Single splenocyte suspensions were prepared and analyzed in the ex vivo reactivation assay or used for DNA isolation
for real time PCR analysis. Data shown in panels A) and D) are means + SD, in A) from 6 mice compiled from two independent experiments and
in D) from three mice from a single experiment. Data shown in panel B) are means + SEM, derived from two experiments. Data shown in panel E)
are derived from a single experiment. In each experiment, splenocytes from 3 mice per group were pooled. The dashed line in panels B) and E)
indicates the point of 63.2% Poisson distribution, determined by nonlinear regression, which is used to calculate the frequency of cells
reactivating lytic replication. In panels C) and F), each symbol represents an individual mouse and the bars represent the mean. The data in C) are
compiled from 2 independent experiments, the data in F) are from a single experiment.
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infected cells in the spleen during latency amplification
while it did not reduce lung infection after i.n. MHV-68
challenge infection [8,19]. In a separate study, however, an
approximately 10-fold reduction in the lytic virus load in
the lungs but no reduction of splenomegaly and of the
number of latently infected spleen cells after vaccination
with dendritic cells pulsed with a MHC class II-restricted
gp150 peptide was observed [20]. Since we did not ob-
serve a reduction in splenomegaly and in the number of
latently infected cells during latency amplification in the
spleen after infection of mice with MHV-68 lacking
gp150, we re-evaluated the effect of vaccination with
gp150. Specifically, we asked i) whether vaccination of
mice with gp150 might induce an anti-gp150 immune re-
sponse and if so, ii) whether this immune response influ-
ences a subsequent MHV-68 challenge infection. For
vaccination, we used gp150-containing exosomes. Exo-
somes are small membrane vesicles which are releasedinto the extracellular compartment during fusion of multi-
vesicular bodies with the plasma membrane and are
secreted by various cell types [21]. Exosomes expressing
tumor antigens have been shown to be immunogenic,
demonstrating the potential of exosomes as vaccines to
generate antitumor responses [21,22]. We produced
gp150-containing exosomes (293/gp150 exosomes) by
transfection of HEK293 cells with an expression plasmid
coding for gp150. Exosomes prepared from untransfected
HEK293 cells (293 exosomes) served as control. While
gp150 was readily detectable by Western Blot in 293/
gp150 exosomes, it was not present in control 293 exo-
somes (Figure 2A). Consistent with data from Stewart
et al. [19], we also detected the gp150 precursor gp130
and alternatively-glycosylated forms of higher molecular
weight (Figure 2A). As shown by flow cytometry, 293/
gp150 exosomes bound to beads coated with polyclonal
anti-MHV-68 antiserum, demonstrating that gp150 is




































Figure 2 Characterization of exosomes. Exosomes were analyzed for overall gp150 content by Western Blot (panel A) and for gp150 surface
content by FACS analysis (panel B). A) Gp150 was detected in purified exosomes and total cell lysates with polyclonal rabbit anti-MHV-68
antibody. Marker sizes (in kD) are indicated on the left. B) Gp150 on the surface of exosomes was detected by binding of exosomes to flow
cytometry Protein G antibody binding beads coated with polyclonal rabbit anti-MHV-68 antibody. Binding of exosomes was visualized by staining
for the exosome marker CD63 using a PE-conjugated anti CD63 monoclonal antibody. Solid black line: beads only; dotted black line: beads + 293
exosomes; grey histogram: beads + 293/gp150 exosomes.
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mice were vaccinated twice (day 0 and 14) with 10 μg
293/gp150 exosomes or, as a control, with the same
amount of 293 exosomes. Nineteen days after the second
vaccination (day 33), sera of immunized mice were ana-
lyzed by ELISA for the presence of anti-gp150 antibodies,
and gp150-specific T cells were quantified by ELISPOT.
Vaccination with 293/gp150 exosomes, but not with con-
trol 293 exosomes, induced both humoral (Figure 3A) and
cellular gp150-specific immune responses (Figure 3B).
The level of the humoral immune response induced by
the 293/gp150 exosome vaccination was comparable to
that after infection with MHV-68 (Figure 3A). Next, we
challenged vaccinated mice by i.n. infection with 5 × 104
PFU of MHV-68 on day 28 and analyzed both lytic and la-
tent infection. Lytic replication was analyzed five days after
infection (day 33) by determining lytic virus titers in lung
homogenates by standard plaque assay. As shown in
Figure 4A, immunization did not influence the amount of
lytic virus present in the lungs of infected mice. This result
is consistent with previous findings after immunization
with a recombinant vaccinia virus expressing gp150 [8,19]
but different to findings after vaccination with dendritic
cells pulsed with a MHC class II-restricted gp150 peptide
[20]. We also analyzed splenomegaly and the number of
latently infected cells in the spleen seventeen days after in-
fection (day 45). We found no evidence for an influence of
vaccination with gp150 on splenomegaly (Figure 4B), on
the number of reactivating cells as determined by limiting
dilution reactivation assay (Figure 4C) and on the latent
viral load as measured by quantitative real time PCR
(Figure 4D). While these results are consistent with thedata from Woodland et al. [20], they deviate from findings
reported by Stewart et al. [19]. The latter might be due to
differences of several parameters between the study by
Stewart and our study: i) different immunization routes
and schedules (subcutaneous vaccination with boost after
28 days vs. intraperitoneal (i.p.) vaccination with boost
after 14 days); ii) age and strain of mice (4 week old
BALB/c mice vs. 6–8 week old C57BL/6 mice); iii) time
and dose of challenge infection (challenge with 4 × 105
PFU 28 days after second vaccination vs. challenge with
5× 104 PFU 14 days after second vaccination) and iv)
methods and time points used for read-out (virus neutral-
isation assay, spleen cell number and infectious center
assay at days 10, 14, 21 and 28 after challenge infection vs.
ELISA, ELISPOT, spleen weight and ex vivo limiting dilu-
tion reactivation assay at day 17 after challenge infection).
Most importantly, while we used gp150-containing exo-
somes for vaccination, Stewart et al. used recombinant
vaccinia virus expressing gp150. Recombinant vaccinia
viruses expressing foreign antigens are powerful vaccines
[23]. Yet, vaccination with gp150-containing exosomes
also induced a considerable humoral and cellular immune
response but did not influence a subsequent MHV-68
challenge infection. This is consistent with more recent
findings by Gillet et al. [10], proposing that gp150 is not a
significant neutralization target but rather acts as an im-
munogenic decoy.
Conclusions
Taken together, our data suggest that gp150 is dispens-
able for latency amplification. Vaccination with gp150-























































Figure 3 Immune response after vaccination with gp150-containing exosomes. Mice were vaccinated twice (day 0 and 14) with gp150-
containing exosomes (293/gp150) or as a control, with exosomes prepared from untransfected 293 cells (293). Nineteen days after the second
vaccination (day 33), sera were analyzed by ELISA for the presence of anti-gp150 antibodies (panel A). For comparison, antibody levels of MHV-68
infected mice (> 2 weeks after infection) are shown. The presence of gp150-specific T-cells was detected by re-stimulation of splenocytes with
exosomes (+/− gp150) and subsequent quantification of activated T-cells by IFN-γ-ELISPOT (panel B). Data shown are means + SD derived from
eight (293 exosomes), seven (293/gp150 exosomes) and two (MHV-68 infected) mice, respectively. The Student’s t-test (unpaired) was used for
statistical analysis.
Ruiss et al. Virology Journal 2012, 9:107 Page 5 of 8
http://www.virologyj.com/content/9/1/107MHV-68 challenge infection, even though it induced a
strong humoral and cellular immune response.
Methods
Cell lines and virus stocks
BHK-21 cells (ATCC CCL-10) were grown in Glasgow-
MEM (PAN Biotech, Aidenbach, Germany) supplemented
with 5% fetal calf serum (FCS), 5% tryptose phosphate
broth, 2 mM L-glutamine, 100 U/mL penicillin and
100 μg/mL streptomycin. NIH3T3 cells (ATCC CRL-
1658) and HEK293 cells (ATCC CRL-1573) were grown
in DMEM (Invitrogen, Darmstadt, Germany) supplemen-
ted with 10% FCS, 2 mM L-glutamine, 100 U/mL penicil-
lin and 100 μg/mL streptomycin. Working stocks of
viruses were prepared as previously described [24]. Briefly,
stocks were grown by infecting BHK-21 cells. After show-
ing complete cytopathic effect (CPE), BHK-21 cells were
harvested and the supernatant was used as working stock
after two times freezing/thawing the cells and removing
cell debris by centrifugation. Virus titers were determined
by plaque assays. Briefly, 10-fold dilutions were incubated
on BHK-21 cells for 90 min at 37 °C. After removing the
inoculum, cells were incubated for 5 days at 37 °C with
fresh medium containing methylcellulose. Cells were
stained with 0.1% crystal violet solution to determine the
number of plaques.
In vivo experiments
Six to eight weeks old C57BL/6 or BALB/c mice were
purchased from Charles River Laboratories (Sulzfeld,Germany) and housed in individually ventilated cages
(IVC) during the MHV-68 infection period. Mice were
infected intranasally (i.n.) with 5 × 104 plaque forming
units (PFU) of MHV-68. Prior to i.n. infection, mice
were anesthetized with ketamine and xylazine. To deter-
mine lytic virus titers, the lungs were harvested and
homogenized using the FASTPREPW-24 instrument (MP
Biomedicals, Heidelberg, Germany). After two times
freezing and thawing the homogenates, plaque assays
were performed with 10-fold dilutions as described
above. To determine the frequency of cells carrying virus
reactivating from latency, spleens were harvested, single
splenocyte suspensions were prepared and analyzed in
an ex vivo limiting dilution reactivation assay as
described [25]. Briefly, serial threefold dilutions of
infected mouse splenocytes were plated on monolayers
of 1 × 104 low-passage NIH3T3 cells per well in 96-well
tissue culture plates. 24 wells were plated per dilution
(starting with 1,5 × 105 cells/well). NIH3T3 cells were
screened microscopically for a viral cytopathic effect
(cpe) for up to 3 weeks. To differentiate between latently
infected cells and infectious virus in the samples, serial
threefold dilutions of spleen cells were plated before or
after mechanical disruption of viable cells (by two
freeze-thaw cycles). No infectious virus was detected in
samples of mechanically disrupted cells (data not
shown). Frequencies of reactivating cells were calculated
on the basis of the Poisson distribution by determining
the cell number at which 63.2% of the wells scored posi-




















































































Figure 4 Vaccination with gp150-containing exosomes does not affect a subsequent MHV-68 challenge infection. A) Virus titers in the
lung, B) Spleen weights, C) Ex vivo reactivation of splenocytes and D) Viral genomic load in the spleen. Mice were vaccinated twice (day 0 and
14) with gp150-containing exosomes (293/gp150) or as a control, with exosomes prepared from untransfected 293 cells (293). On day 28, mice
were challenged by i.n. infection with 5 × 104 PFU. A) Lytic replication was analyzed five days after infection (day 33) by determining virus titers in
lung homogenates by standard plaque assay. Each symbol represents an individual mouse and the bars represent the mean. The data are
compiled from 2 independent experiments. B) to D) Seventeen days after infection (day 45), spleens were harvested and the spleen weights
were taken (panel B). Single splenocyte suspensions were prepared and analyzed in the ex vivo reactivation assay (panel C) or used for DNA
isolation for real time PCR analysis (panel D). Data shown in panel B) are means + SD from 8 mice compiled from two independent experiments.
Data shown in panel C are means + SEM compiled from two independent experiments. In each experiment, splenocytes from 5 and 3 mice per
group, respectively, were pooled. The dashed line in panel C) indicates the point of 63.2% Poisson distribution, determined by nonlinear
regression, which is used to calculate the frequency of cells reactivating lytic replication. In panel D), each symbol represents an individual mouse
and the bars represent the mean. The data are compiled from 2 independent experiments. There were no significant differences in virus titers in
the lung (panel A), spleen weights (panel B), ex vivo reactivation of splenocytes (panel C) and viral genomic load in the spleen (panel D). The
two-tailed Student’s t-test was used for statistical analysis.
Ruiss et al. Virology Journal 2012, 9:107 Page 6 of 8
http://www.virologyj.com/content/9/1/107with protocols approved by the local Animal Care and
Use Committee (District Government of Upper Bavaria;
permit number 124/08).
Measurement of latent viral load by quantitative real
time PCR
Viral load in the spleens of infected mice was determined
by quantitative real-time PCR using the ABI 7300 RealTime PCR System (Applied Biosystems, Foster City, CA)
as described [26]. Briefly, DNA was extracted from spleen
cells using the QIAmp DNA Mini Kit (Qiagen, Hilden,
Germany) and quantified by UV spectrophotometry.
Amplification of 100 ng of DNA per reaction was per-
formed with Taqman universal PCR master mix and uni-
versal cycling conditions (Applied Biosystems, Foster City,
CA). Using primers and probes as described [27], a 70 bp
Ruiss et al. Virology Journal 2012, 9:107 Page 7 of 8
http://www.virologyj.com/content/9/1/107region of the MHV-68 glycoprotein B (gB) gene was amp-
lified and viral DNA copy numbers were quantified. A
standard curve was created using known amounts
of a plasmid containing the HindIII-N fragment of MHV-
68 encompassing the gB gene. The murine ribosomal pro-
tein L8 (rpl8) was amplified in parallel and used to
normalize for input DNA between samples. The
primer and probe sequences for L8 were as follows:
Forward: 5’-CATCCCTTTGGAGGTGGTA-3’; Reverse: 5’-
CATCTCTTCGGATGGTGGA-3’ and Probe: 5’-ACCAC-
CAGCACATTGGCAAACC-3’. A standard curve for
rpl8 was generated by serial 10 fold dilution of a plas-
mid containing rpl8 (RZPD clone IRAVp968B01123D6,
RZPD, Berlin, Germany). The data are presented as
viral genome copy numbers relative to the copy number
of L8. The quantification limit was set at 50 copies per
sample, according to published recommendations [28].
Production and characterization of gp150-carrying
exosomes
To generate gp150-carrying exosomes, 293 cells were
transfected with an expression plasmid coding for gp150,
and three days later, exosomes were prepared from the
supernatant. Control exosomes were prepared in the same
way from untransfected 293 cells. Briefly, exosomes were
subjected to sequential centrifugation steps (300 g for
10 min, 5000 g for 10 min and 100.000 g for 120 min).
The pelleted exosomes were washed and resuspended in
PBS containing proteinase inhibitors (Complete Mini Pro-
teinase Inhibitor Cocktail, Roche, Penzberg, Germany).
The protein content was analyzed in a BCA protein
microassay (Pierce, Rockford, USA). Exosomes were ana-
lyzed for overall gp150 content by Western Blot and for
gp150 surface content by FACS analysis. For Western
Blotting, 30 μg of exosomes were lysed in sample buffer,
separated by SDS-PAGE and transferred onto a Hybond-
ECL membrane (GE Healthcare, Munich, Germany).
gp150 was detected by incubating the membrane with
polyclonal rabbit anti-MHV-68 antibody [29], followed
by peroxidase-conjugated donkey anti-rabbit antibody
(Jackson Laboratories, Newmarket, UK). Blots were devel-
oped using ECL reagent (GE Healthcare, Munich, Ger-
many) according to the instructions of the manufacturer.
For FACS analysis, flow cytometry Protein G antibody
binding beads (Polysciences Europe GmbH, Eppelheim,
Germany) were coated with polyclonal rabbit anti-MHV-
68 antibody for 30 min at room temperature. After wash-
ing with PBS and blocking with RPMI/10% FCS, beads
were incubated with exosomes for two hours at room
temperature. After washing, bound exosomes were
detected by incubation with PE-conjugated anti CD63
monoclonal antibody (Immunotools, Friesoythe, Ger-
many). CD63, a member of the tetraspanin family, is a
marker protein for exosomes [21].Vaccination with exosomes and challenge infection
Mice were vaccinated twice (day 0 and 14) with gp150-
containing exosomes (293/gp150 exosomes) or as a con-
trol, with exosomes prepared from untransfected 293
cells (293 exosomes). Vaccination was performed i.p.
with a mixture of 10 μg of exosomes and 10 nmol CpG-
ODN 1668 (InvivoGen, San Diego, USA) in a total vol-
ume of 200 μl PBS per mouse. Fourteen days after the
second vaccination (day 28), mice were challenged with
5 × 104 PFU of MHV-68.
ELISPOT assay for determination of gp150-specific T cells
To determine gp150-specific T-cells, splenocytes from
vaccinated mice were plated onto precoated ELISPOT
plates in a densitiy of 106 cells/well and restimulated
in vitro with 10 μg of exosomes (+/− gp150). After 24 h,
activated T-cells were quantified using a mouse IFN-γ-
ELISPOT Kit (eBioscience, Frankfurt, Germany) as
recommended by the manufacturer, and spots were
counted by inspection under a dissecting microscope.
ELISA for determination of gp150-specific antibodies
To determine gp150-specific antibodies in sera of vacci-
nated mice, Nunc Maxisorp plates (Nunc, Wiesbaden,
Germany) were coated overnight with 3 μg/ml of MHV-
68 lysate. The lysate was prepared by disruption of
MHV-68 via dilution in PBS with 0.05% Triton X-100 as
described [30]. After washing with PBS/Tween, plates
were blocked with RPMI containing 10% FCS for 1 hour
and washed again. Then, fifty-fold serum dilutions were
incubated for two hours. After washing, bound antibody
was detected with HRP-conjugated rat anti-mouse anti-
body (Promega, Mannheim, Germany) using TMB (Bec-
ton Dickinson, Heidelberg, Germany) as substrate and,
after stopping with 1 M phosphoric acid, reading the
absorbancy at 450 nm.
Statistical methods
If not otherwise indicated, data were analyzed by two-
tailed Student’s t-test.
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